trabedersen

DRUG2 trials

Sponsors

Isarna Therapeutics GmbH, University of Nebraska

Conditions

Anaplastic AstrocytomaGlioblastomaNon-small Cell Lung Cancer

Phase 1

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

RecruitingNCT06579196

University of NebraskaNon-small Cell Lung Cancer

Start: 2025-05-12End: 2029-02-28Target: 45Updated: 2025-07-24

Phase 3

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

TerminatedNCT00761280

Isarna Therapeutics GmbHAnaplastic Astrocytoma, Glioblastoma

Start: 2008-12-31End: 2012-06-30Updated: 2014-11-14

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations